Late diagnosis means progression to severe forms of the disease
No plenário da Assembleia Legislativa de Goiás, uma proposta legislativa busca transformar em política pública a resposta a uma crise silenciosa: a pancreatite aguda, doença que ceifou quase 20 mil vidas no Brasil em uma década e que encontra, nos hábitos contemporâneos e nos novos medicamentos para emagrecer, um terreno cada vez mais fértil. O deputado Virmondes Cruvinel apresenta o projeto como uma questão de coordenação — entre níveis de atenção à saúde, entre conhecimento clínico e prática cotidiana, entre a capital e o interior do estado. É o reconhecimento de que mortes evitáveis exigem respostas estruturadas, não apenas boas intenções.
- O Brasil registrou mais de 200 mil internações por pancreatite aguda entre 2019 e 2024, e a taxa de mortalidade hospitalar sobe de forma constante após os 55 anos — o silêncio epidemiológico tem um custo humano mensurável.
- Medicamentos para emagrecer como Ozempic e Wegovy, amplamente adotados num estado onde quase 71% dos adultos estão acima do peso, apresentam taxa de pancreatite no Brasil mais que o dobro da média global, acendendo um alerta regulatório urgente.
- No interior de Goiás, a ausência de exames laboratoriais específicos e de imagem retarda o diagnóstico, transformando casos tratáveis em formas graves da doença — a distância geográfica vira sentença clínica.
- O projeto propõe costurar atenção primária, emergências e hospitais especializados numa rede contínua, apostando que a integração entre níveis de cuidado é o elo que falta para evitar mortes desnecessárias.
- A proposta tramita agora na comissão de constituição e justiça da Alego, onde um relator prepara seu parecer — o que vier a seguir definirá se Goiás passa a tratar a pancreatite como prioridade de saúde pública ou como estatística.
Na Assembleia Legislativa de Goiás, o deputado Virmondes Cruvinel apresentou um projeto de lei para criar uma política estadual de prevenção, diagnóstico e tratamento da pancreatite aguda — inflamação súbita do pâncreas que pode evoluir, em horas, para falência de órgãos e morte. O argumento central é epidemiológico: entre 2019 e 2024, o Brasil acumulou mais de 200 mil internações pela doença, e na década anterior quase 20 mil pessoas morreram em decorrência dela.
Em Goiás, os principais fatores de risco são cálculos biliares e consumo excessivo de álcool. Mas um elemento novo preocupa: os medicamentos para emagrecer da classe dos agonistas GLP-1, como semaglutida, têm sido associados a casos de pancreatite. Entre 2020 e 2025, a Anvisa registrou 145 eventos adversos suspeitos ligados a essas drogas, com seis mortes. A taxa brasileira de pancreatite entre usuários é de 5,9% — mais que o dobro da média global de 2,4%. Num estado onde 70,9% dos adultos estão com sobrepeso e 36,3% têm obesidade, a demanda por esses medicamentos é alta, e o risco, proporcional.
O projeto prevê campanhas de educação sobre fatores modificáveis — álcool, tabagismo, obesidade —, capacitação de profissionais de saúde e adoção de protocolos clínicos reconhecidos. Seu ponto mais crítico é a integração entre atenção primária, serviços de emergência e hospitais especializados. No interior do estado, a falta de exames de imagem e laboratoriais específicos atrasa o diagnóstico e agrava os casos. Cruvinel argumenta que conectar esses níveis de cuidado é indispensável para reduzir internações prolongadas e mortes evitáveis.
Goiânia já concentra três grandes hospitais que atendem casos de pancreatite aguda, recebendo pacientes de municípios menores e estados vizinhos. Uma política estruturada, defende o deputado, ampliaria a capacidade diagnóstica na ponta do sistema, aliviando esses centros e intervindo quando o tratamento ainda é mais eficaz. O projeto segue agora para análise na comissão de constituição e justiça, onde o deputado Dr. George Morais prepara o relatório.
In the state legislature of Goiás, a proposal is taking shape to address a medical crisis that has quietly claimed thousands of lives. Deputy Virmondes Cruvinel has introduced legislation to establish a comprehensive state policy for preventing, diagnosing, and treating acute pancreatitis—a sudden inflammation of the pancreas that can spiral from manageable to catastrophic within hours.
The pancreas is a workhorse organ, responsible for breaking down fats and proteins and regulating blood sugar. When it becomes inflamed, the consequences can be severe. The condition can progress from mild, self-limiting cases to tissue death, organ failure, sepsis, and death. The urgency is real: most cases demand immediate medical intervention to prevent complications that can prove fatal. Cruvinel argues that this clinical and epidemiological weight demands a coordinated response.
The numbers tell a stark story. Between 2019 and 2024, Brazil recorded more than 200,000 hospitalizations for acute pancreatitis. In the decade from 2013 to 2023, nearly 20,000 people died from the condition. The disease strikes hardest in middle age—those between 40 and 49 account for the largest share of cases, with men representing 52 percent of the total. Hospital mortality averages around 5 percent, but climbs steadily after age 55, concentrating among men in their sixties and seventies.
Two risk factors dominate in Goiás specifically: gallstones, which form from fat accumulation in the gallbladder, and excessive alcohol consumption. But a newer threat has emerged. In recent years, weight-loss medications—drugs with names like Ozempic, Wegovy, and Mounjaro—have been linked to pancreatitis. These medications belong to a class called GLP-1 agonists, compounds that mimic a hormone involved in blood sugar control. Between 2020 and 2025, Brazil's health regulator documented 145 suspected adverse events tied to these drugs, including six deaths. The problem appears worse here than elsewhere. While the global rate of pancreatitis among semaglutida users stands at 2.4 percent, in Brazil it reaches 5.9 percent—more than double. By comparison, the United Kingdom's medicines regulator recorded 1,296 cases of pancreatitis linked to these drugs over eighteen years, with 19 fatalities.
Cruvinel points to a troubling reality in Goiás: obesity and overweight are climbing. In 2025, data from the public health nutrition surveillance system showed that 36.3 percent of adults in Goiânia had obesity, and 70.9 percent were overweight. This creates a large population for whom weight-loss drugs hold appeal—and risk. Even though the health regulator now requires prescriptions to be retained before dispensing, as with antibiotics, the need for state-level guidance remains urgent.
The proposal's framework is practical. It calls for public education campaigns targeting modifiable risk factors: alcohol abuse, smoking, obesity, and gallstones. It mandates that health professionals receive current, evidence-based information about the disease. It pushes adoption of recognized clinical protocols for diagnosis, severity assessment, and treatment. Most critically, it demands coordination between primary care clinics, emergency services, and specialized hospitals—a chain of care that currently breaks down, especially in smaller towns in the interior.
This last point cuts to the heart of the problem. In rural Goiás, access to specific blood tests and imaging services is limited. Diagnosis comes late, and late diagnosis means progression to severe forms of the disease. Cruvinel argues that linking primary care to emergency networks to specialized centers is not optional—it is essential to reducing prolonged hospitalizations and preventable deaths.
Goiânia itself hosts three major hospitals that already handle acute pancreatitis cases: the State Emergency Hospital Governador Otávio Lage de Siqueira, the Federal University of Goiás Hospital das Clínicas, and Hospital Alberto Rassi. Patients from smaller towns and neighboring states already travel to these centers for care. A structured policy, Cruvinel contends, would expand prevention and diagnostic capacity at every level, easing the burden on these central facilities and catching cases earlier, when intervention is most effective.
The bill is now moving through the legislature's constitutional and legal affairs committee, where Deputy Dr. George Morais is preparing a report. What emerges from that process will shape how Goiás responds to a disease that has already cost thousands of lives and continues to claim more.
Citas Notables
The urgent nature of most cases demands immediate medical intervention to prevent potentially fatal complications, giving the disease undeniable clinical and epidemiological importance.— Deputy Virmondes Cruvinel
Coordination between primary care, emergency networks, and specialized centers is essential to reducing prolonged hospitalizations and preventable deaths.— Deputy Virmondes Cruvinel
La Conversación del Hearth Otra perspectiva de la historia
Why does a state need its own pancreatitis policy? Isn't this a medical issue that doctors already understand?
Doctors understand the disease, yes. But understanding and access are different things. In small towns in Goiás, there are no labs to run the specific blood tests that confirm pancreatitis. By the time a patient reaches a hospital with imaging capability, hours have passed. The policy isn't about teaching doctors medicine—it's about building the infrastructure and coordination so diagnosis happens fast enough to matter.
The weight-loss drugs seem like a new wrinkle. Are they actually dangerous, or is this overblown?
The data suggests real danger, at least in Brazil. The global rate of pancreatitis in people using these drugs is 2.4 percent. Here it's 5.9 percent. That's not a small difference. Six people have died. The drugs work—people do lose weight—but the risk profile appears steeper in Brazil than elsewhere, and we don't fully understand why.
Why would the risk be higher in Brazil than in other countries?
That's the question no one can answer yet. It could be how the drugs are being used—less medical supervision, higher doses, people with other risk factors taking them. It could be something about the population. But the pattern is clear enough that the legislator thinks the state needs to warn doctors and patients explicitly.
If the regulator already requires prescriptions to be retained, what more can a state policy do?
Retention stops casual refills, but it doesn't educate. A state policy means every primary care clinic gets guidance on who should and shouldn't take these drugs, what to watch for, when to refer. It means public campaigns explaining the risks. It's the difference between a rule and a culture of caution.
What happens to someone with acute pancreatitis if they don't get treated quickly?
The organ starts to digest itself. Tissue dies. Other organs fail. Infection sets in. The mortality rate is already 5 percent in hospitals. In the community, untreated, it's much worse. Speed matters enormously.